AP2003002924A0 - 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators - Google Patents
2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulatorsInfo
- Publication number
- AP2003002924A0 AP2003002924A0 APAP/P/2003/002924A AP2003002924A AP2003002924A0 AP 2003002924 A0 AP2003002924 A0 AP 2003002924A0 AP 2003002924 A AP2003002924 A AP 2003002924A AP 2003002924 A0 AP2003002924 A0 AP 2003002924A0
- Authority
- AP
- ARIPO
- Prior art keywords
- compounds
- disorders
- diarylpyridines
- diarylpyrazines
- diarylpyrimidines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29748301P | 2001-06-12 | 2001-06-12 | |
| PCT/US2002/016518 WO2002100838A1 (en) | 2001-06-12 | 2002-05-22 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2003002924A0 true AP2003002924A0 (en) | 2003-12-31 |
Family
ID=23146501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2003/002924A AP2003002924A0 (en) | 2001-06-12 | 2002-05-22 | 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6887875B2 (enExample) |
| EP (1) | EP1399428A1 (enExample) |
| JP (1) | JP2005500286A (enExample) |
| AP (1) | AP2003002924A0 (enExample) |
| BG (1) | BG108427A (enExample) |
| CA (1) | CA2450262A1 (enExample) |
| EC (1) | ECSP034898A (enExample) |
| HR (1) | HRP20031096A2 (enExample) |
| HU (1) | HUP0400179A3 (enExample) |
| IL (1) | IL159058A0 (enExample) |
| IS (1) | IS7060A (enExample) |
| MX (1) | MXPA03011391A (enExample) |
| PL (1) | PL367476A1 (enExample) |
| RU (1) | RU2003136151A (enExample) |
| TN (1) | TNSN03133A1 (enExample) |
| WO (1) | WO2002100838A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4368001A (en) * | 2000-03-16 | 2001-09-24 | Neurogen Corporation | 5-substituted arylpyrimidines |
| BR0309551A (pt) | 2002-04-26 | 2005-02-09 | Upjohn Co | Derivados substituìdos de pirazina |
| DE60305053T2 (de) | 2002-08-19 | 2006-08-31 | Glaxo Group Ltd., Greenford | Pyrimidinderivate als selektive cox-2-inhibitoren |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
| AU2003278542A1 (en) * | 2002-11-21 | 2004-06-15 | Pharmacia & Upjohn Company Llc | Pyrazine compounds as crf modulators |
| BRPI0416853A (pt) | 2003-11-24 | 2007-02-13 | Hoffmann La Roche | pirazolila e imidazolila pirimidinas |
| BRPI0513211A (pt) * | 2004-07-14 | 2008-04-29 | Basf Ag | composto, agente pesticida, combinação, e, processos para combater fungos nocivos fitopatogênicos, e pestes animais em agricultura |
| TW200637556A (en) * | 2005-01-31 | 2006-11-01 | Basf Ag | Substituted 5-phenyl pyrimidines I in therapy |
| BRPI0614262A2 (pt) * | 2005-08-02 | 2011-03-15 | Lexicon Pharmaceuticals Inc | aril piridinas e métodos para uso das mesmas |
| TW200908984A (en) * | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| US7932256B2 (en) * | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
| WO2011051478A1 (en) * | 2009-10-30 | 2011-05-05 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9351494B2 (en) | 2013-05-03 | 2016-05-31 | Inscent, Inc. | Honeybee repellents and uses thereof |
| US9357781B2 (en) | 2013-05-03 | 2016-06-07 | Inscent, Inc. | Honeybee repellents and uses thereof |
| CN105254576A (zh) * | 2014-02-26 | 2016-01-20 | 中国科学院长春应用化学研究所 | 一种谷氨酸二酮哌嗪的制备方法 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| JP2022074173A (ja) * | 2019-03-18 | 2022-05-18 | 住友化学株式会社 | ２，５－ジクロロピラジンの製造方法 |
| CN112142716B (zh) * | 2020-10-29 | 2021-08-31 | 山东新时代药业有限公司 | 一种5元杂芳基取代的吡嗪衍生物及其应用 |
| CN113429354A (zh) * | 2021-07-22 | 2021-09-24 | 广东嘉博制药有限公司 | 一种盐酸甲氧明聚合物杂质及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1463813A (fr) * | 1964-02-26 | 1966-07-22 | Ciba Geigy | Nouvelles amino-phénylcétones et procédé pour leur préparation |
| US3660404A (en) * | 1969-02-24 | 1972-05-02 | Du Pont | U.v.-absorbing ortho-hydroxyphenyl substituted bipyrimidyls |
| DE2064380C3 (de) * | 1970-12-30 | 1981-01-22 | Hoechst Ag, 6000 Frankfurt | Lichtempfindliches Gemisch |
| JPS625970A (ja) | 1985-03-15 | 1987-01-12 | Terumo Corp | ピラジン誘導体およびこれを含有する血小板凝集抑制剤 |
| EP0339252B1 (en) * | 1988-04-25 | 1996-06-12 | Dainippon Ink And Chemicals, Inc. | 2,5-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same |
| JPH02209873A (ja) * | 1989-02-08 | 1990-08-21 | Dainippon Ink & Chem Inc | 光学活性２，５―ジ置換ピリミジン誘導体 |
| JP2770385B2 (ja) * | 1989-03-16 | 1998-07-02 | セイコーエプソン株式会社 | ピリミジン誘導体 |
| JP3398152B2 (ja) * | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| JPH0948760A (ja) * | 1995-08-03 | 1997-02-18 | Dainippon Ink & Chem Inc | ピリミジン化合物 |
| JP4044175B2 (ja) * | 1996-07-26 | 2008-02-06 | 株式会社半導体エネルギー研究所 | 光学活性化合物及び該化合物を含有する反強誘電性液晶組成物 |
| US6686486B1 (en) * | 1997-05-07 | 2004-02-03 | Padma Marwah | Process for effecting allylic oxidation |
| SE9702651D0 (sv) * | 1997-07-09 | 1997-07-09 | Astra Pharma Prod | Novel compounds |
| PL341984A1 (en) * | 1998-01-28 | 2001-05-07 | Shionogi & Co | Novel tricycle compounds |
| CO5210940A1 (es) * | 1999-05-04 | 2002-10-30 | Novartis Ag | Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen |
| ATE307121T1 (de) * | 2000-02-16 | 2005-11-15 | Neurogen Corp | Substituierte arylpyrazine |
-
2002
- 2002-05-22 HR HR20031096A patent/HRP20031096A2/xx not_active Application Discontinuation
- 2002-05-22 EP EP02737167A patent/EP1399428A1/en not_active Withdrawn
- 2002-05-22 WO PCT/US2002/016518 patent/WO2002100838A1/en not_active Ceased
- 2002-05-22 MX MXPA03011391A patent/MXPA03011391A/es unknown
- 2002-05-22 PL PL02367476A patent/PL367476A1/xx not_active Application Discontinuation
- 2002-05-22 RU RU2003136151/04A patent/RU2003136151A/ru not_active Application Discontinuation
- 2002-05-22 IL IL15905802A patent/IL159058A0/xx unknown
- 2002-05-22 AP APAP/P/2003/002924A patent/AP2003002924A0/en unknown
- 2002-05-22 JP JP2003503606A patent/JP2005500286A/ja active Pending
- 2002-05-22 CA CA002450262A patent/CA2450262A1/en not_active Abandoned
- 2002-05-22 US US10/154,482 patent/US6887875B2/en not_active Expired - Fee Related
- 2002-05-22 HU HU0400179A patent/HUP0400179A3/hu unknown
-
2003
- 2003-07-08 TN TNPCT/US2002/016518A patent/TNSN03133A1/en unknown
- 2003-11-28 IS IS7060A patent/IS7060A/is unknown
- 2003-12-08 BG BG108427A patent/BG108427A/xx unknown
- 2003-12-12 EC EC2003004898A patent/ECSP034898A/es unknown
-
2005
- 2005-04-04 US US11/098,885 patent/US20050176721A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IS7060A (is) | 2003-11-28 |
| IL159058A0 (en) | 2004-05-12 |
| HUP0400179A2 (hu) | 2004-08-30 |
| BG108427A (bg) | 2005-01-31 |
| WO2002100838A1 (en) | 2002-12-19 |
| TNSN03133A1 (en) | 2005-12-23 |
| JP2005500286A (ja) | 2005-01-06 |
| US20050176721A1 (en) | 2005-08-11 |
| HRP20031096A2 (en) | 2005-08-31 |
| CA2450262A1 (en) | 2002-12-19 |
| EP1399428A1 (en) | 2004-03-24 |
| US6887875B2 (en) | 2005-05-03 |
| HUP0400179A3 (en) | 2004-10-28 |
| US20030119844A1 (en) | 2003-06-26 |
| MXPA03011391A (es) | 2004-07-01 |
| RU2003136151A (ru) | 2005-05-20 |
| PL367476A1 (en) | 2005-02-21 |
| ECSP034898A (es) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN03133A1 (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators | |
| TNSN03119A1 (en) | 5-substituted-2-arylpyridines as crf1 modulators | |
| WO2005028480A3 (en) | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds | |
| WO2005115399A3 (en) | Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands | |
| IL148904A0 (en) | Amino substituted pyrazolo {1,5,-a}-1,5- pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines | |
| EA200600372A1 (ru) | Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1) | |
| WO2002006242A3 (en) | 5-substituted 2-aryl-4-pyrimidinones | |
| MXPA03009439A (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1. | |
| BG106506A (en) | ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a)-1,5-PYRIMIDINES AND PARAZOLO[1,5-a)-1,3,5-TRIAZINES | |
| IL150085A0 (en) | New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | |
| MXPA04002583A (es) | Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1). | |
| YU34898A (sh) | Antagonisti ccr-3 receptora | |
| MXPA03000710A (es) | Ciclopentanoindoles, composiciones que contienen estos compuestos y metodos de tratamiento. | |
| CY1109015T1 (el) | Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
| GB0504828D0 (en) | Therapeutic agents | |
| WO2007133756A3 (en) | Crf1 receptor ligands comprising heteroaryl fused bicycles | |
| JO2359B1 (en) | Benzathene derivatives as agents for modulation of GABA A receptor | |
| WO2005030188A3 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
| YU80902A (sh) | Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže | |
| EP1244452A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
| MXPA05007771A (es) | Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno. | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| WO2002011732A8 (en) | Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists | |
| IL144031A0 (en) | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | |
| MXPA05011410A (es) | Tratamiento de incontinencia con agonistas de 5htc2. |